Omnicell (NASDAQ:OMCL) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a report issued on Friday morning.

A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Wells Fargo & Company increased their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Benchmark reiterated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America restated a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Finally, Barclays upped their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus target price of $50.83.

Omnicell Stock Performance

NASDAQ:OMCL opened at $45.67 on Friday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The firm’s fifty day moving average is $44.20 and its 200-day moving average is $36.89. The firm has a market cap of $2.12 billion, a P/E ratio of -117.10, a P/E/G ratio of 43.97 and a beta of 0.81.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of OMCL. Texas Permanent School Fund Corp raised its holdings in shares of Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after purchasing an additional 479 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Omnicell during the 1st quarter worth approximately $684,000. Inspire Investing LLC boosted its stake in shares of Omnicell by 19.2% in the 1st quarter. Inspire Investing LLC now owns 12,111 shares of the company’s stock worth $354,000 after buying an additional 1,952 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after acquiring an additional 626 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Omnicell during the first quarter valued at approximately $227,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.